[MASCA-model of the biochemical-pharmacological drug research. Part 3: Structure-activity relationships and KANORA (author's transl)]
[Article in
German]
- PMID: 1242657
Item in Clipboard
[MASCA-model of the biochemical-pharmacological drug research. Part 3: Structure-activity relationships and KANORA (author's transl)]
[Article in
German]
Arzneimittelforschung.
1975 Sep.
Abstract
The KANORA (multivariate regression and correlation analysis) leads to a combination with the multivariate structure-activity analysis which encloses the time-, dose-response and biological screening analysis. Drug-receptor interactions can be considered in connection with structure-action relationship. The importance of the analysis of "nonsense"-correlations (by using the partial correlation) and the model II of regression analysis is demonstrated.
Similar articles
-
[MASCA-model of the biochemical-pharmacological drug research/ part 4: Structure-activity relationships and MANOVA (author's transl)].Arzneimittelforschung. 1975 Oct;25(10):1475-6. Arzneimittelforschung. 1975. PMID: 1243023 German.
-
[MASCA-model of the biochemical-pharmacological drug research / part 5: Structure-activity relationships and MACOVA (author's transl)].Arzneimittelforschung. 1975 Nov;25(11):1745. Arzneimittelforschung. 1975. PMID: 1243081 German. No abstract available.
-
[MASCA-model of biochemical-pharmacological drug research/Part VIII: Examples (author's transl)].Arzneimittelforschung. 1976 Feb;26(2):185-7. Arzneimittelforschung. 1976. PMID: 7279 German.
-
[Current problems in effective-substance research. 9. Parameter-free methods for the structure-activity analysis].Pharmazie. 1976;31(1):1-14. Pharmazie. 1976. PMID: 768997 Review. German. No abstract available.
-
Theoretical approaches to drug design and biological activity: II. Multivariate structure-activity relationships in combination with the multivariate bioassay (MASCA model).Med Res Rev. 1983 Oct-Dec;3(4):435-98. doi: 10.1002/med.2610030404. Med Res Rev. 1983. PMID: 6358723 Review. No abstract available.